What is the recommended dosing schedule and dosage of Genevac‑B (hepatitis B vaccine) for different age groups?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Genevac-B Dosing Recommendations

Genevac-B (also marketed as Engerix-B) should be administered as 10 mcg (0.5 mL) for children birth through 19 years of age and 20 mcg (1.0 mL) for adults ≥20 years, given in a 3-dose series at 0,1, and 6 months. 1

Standard Dosing by Age Group

Infants and Children (Birth through 10 years)

  • Dose: 10 mcg (0.5 mL)
  • Schedule: 0,1,6 months
  • Route: Intramuscular in anterolateral thigh (preferred in infants) 1

Adolescents (11-19 years)

  • Dose: 10 mcg (0.5 mL)
  • Schedule: 0,1,6 months
  • Route: Intramuscular in deltoid 1

Adults (≥20 years)

  • Dose: 20 mcg (1.0 mL)
  • Schedule: 0,1,6 months
  • Route: Intramuscular in deltoid 1

The 2022 ACIP guidelines confirm these dosing recommendations align with current universal hepatitis B vaccination recommendations for adults aged 19-59 years 2.

Special Populations

Hemodialysis Patients and Immunocompromised Adults (≥20 years)

  • Dose: 40 mcg (2.0 mL) - given as two 20 mcg injections
  • Schedule: 4 doses at 0,1,2, and 6 months
  • Monitoring: Annual antibody testing recommended; give booster when anti-HBs falls below 10 mIU/mL 1

This higher dose and 4-dose schedule is critical because hemodialysis patients achieve lower antibody titers and lose protection more rapidly than healthy individuals 1.

Infants Born to HBsAg-Positive Mothers

  • Dose: 10 mcg (0.5 mL)
  • Schedule: 0,1,6 months (standard) OR 0,1,2,12 months (alternate)
  • Critical: Must also receive HBIG in addition to vaccine 1

Alternate Schedules

Accelerated Schedule (for recent exposure or high-risk travel)

  • Children/Adolescents: 10 mcg at 0,1,2,12 months
  • Adults: 20 mcg at 0,1,2,12 months
  • Rationale: Provides faster initial protection (99% seroprotected by month 3), with the 12-month dose ensuring prolonged maintenance 1

Extended Schedule (for low-risk populations)

  • Ages 5-16 years: 10 mcg at 0,12,24 months
  • Note: Only appropriate when extended schedule is acceptable based on low exposure risk 1

Administration Details

Route and Site

  • Primary route: Intramuscular injection
  • Infants <12 months: Anterolateral thigh (1-inch, 23-gauge needle)
  • Toddlers/children ≤10 years: Deltoid (5/8-inch, 25-gauge needle)
  • Older children/adults: Deltoid (1-inch, 23-gauge needle) 1

Critical Caveat - Avoid Gluteal Injection

Never administer in the gluteal region - this results in suboptimal immune response 1. This is a common error that significantly reduces vaccine efficacy.

Subcutaneous Administration

  • Only for: Patients at risk of hemorrhage (e.g., hemophiliacs)
  • Warning: Results in lower antibody titers and increased local reactions including subcutaneous nodules
  • Use sparingly: Reserve for patients with true contraindication to IM injection 1

Interrupted Series Management

If the vaccination schedule is interrupted 1:

  • Do not restart the series - simply continue where you left off
  • After first dose delayed: Give second dose ASAP; separate doses 2 and 3 by ≥8 weeks
  • After second dose delayed: Give third dose ASAP
  • Minimum intervals:
    • First to second dose: 4 weeks
    • Second to third dose: 8 weeks
    • First to third dose: 16 weeks

Doses given ≤4 days before minimum interval are considered valid.

Evidence Quality and Clinical Performance

Research data from India demonstrates that the 10 mcg dose of GeneVac-B produces excellent immunogenicity in adolescents (geometric mean titer 1373 mIU/mL one month after third dose, with 100% seroprotection maintained at 1 year) 3. In infants, GeneVac-B showed 98% seroconversion and 96% seroprotection rates, comparable to Engerix-B 4.

The vaccine has demonstrated excellent safety, with 98.73% of adverse events being non-serious, and 94.12% of reactions occurring within 3 days (primarily fever, local reactions, and rash) 5.

Preparation

  • Shake well before withdrawal
  • Inspect for particulate matter, discoloration, or cracks
  • Should appear as slightly turbid white suspension
  • Use as supplied - no dilution needed
  • Discard any remaining vaccine in single-dose vial 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.